Professor Thozhukat Sathyapalan

MBBS, MD, FRCP, FACP, SFHEA

Chair in Academic Endocrinology, Diabetes and Metabolism / Honorary Consultant Physician

Role at Hull York Medical School

Thozhukat Sathyapalan (Sathya) is the Chair in Academic Diabetes, Endocrinology and Metabolism in Hull York Medical School, University of Hull and Honorary Consultant Endocrinologist at Hull and East Yorkshire Hospitals NHS Trust, UK. He obtained his undergraduate degree in Medicine from University of Kerala, India in 1996 and his MD (General Medicine) from JIPMER, India. He subsequently did his clinical training in Diabetes and Endocrinology as a Specialist Registrar in Yorkshire Deanery. Sathya was a Clinical Research Fellow in University of Hull and obtained his MD (Diabetes and Endocrinology) in 2009. He was appointed as Senior Lecturer in Hull York Medical School in October 2009, Reader in 2012 and was made Chair in Academic Endocrinology and Metabolism in 2016.

Biography
  • MBBS, Trivandrum Medical College, India 1990-1996
  • MD (General Medicine), JIPMER, India 1997-2000
  • Postgraduate Clinical Training (Grampian University Hospitals and Yorkshire Deanery) 2001-2009
  • Clinical Research Fellow, University of Hull 2006-2008
  • Senior Lecturer, Hull York Medical School 2009-2012
  • Reader, Academic Diabetes, Endocrinology and Metabolism 2013-2016
  • Chair, Academic Diabetes, Endocrinology and Metabolism 2016 -
Research

His main area of interest is on modulation of cardiovascular risk through pharmacological and nutritional interventions in insulin resistant states such as obesity, polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus.  He is interested in traditional as well as novel risk factors, specifically endocrine disruptors.

Teaching

Postgraduate (clinical)

  • Organise and lead the Continuing Medical Education programme for endocrine trainees and Consultants in Diabetes and Endocrinology for Health Education Yorkshire and the Humber. RCP-accredited. Delivered by national and international speakers.
  • Educational and Clinical Supervisor for Foundation year trainees, Core Medical trainees and Specialty Trainees in Endocrinology and diabetes

Undergraduate

  • Delivering plenary lectures for Hull York Medical School students
  • Phase II Student Selected Components (SSCs) on ‘patient pathway through research’
  • Critically appraised topic (CAT) assessment for Phase II students
  • Thyroid teaching clinics and diabetes teaching clinics for Hull York Medical School Year 4 students
  • Multi-disciplinary clinical teaching for Year 3 students: type 1 and type 2 diabetes, dedicated sessions with diabetes specialist nurses, podiatrists, and dieticians
  • OSLER and OSCE examiner for Hull York Medical School Year 4 and 5 medical students
Publications

1. Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Hypoglycemia in Type 2 Diabetes exacerbates Amyloid-related proteins associated with dementia. Diabetes Obes Metab. Oct 7 2020;doi:10.1111/dom.14220

2. Danta CC, Boa AN, Bhandari S, Sathyapalan T, Xu SZ. Recent Advances in Drug Discovery for Diabetic Kidney Disease. Expert Opin Drug Discov. Oct 1 2020;doi:10.1080/17460441.2021.1832077

3. Draicchio F, van Vliet S, Ancu O, et al. Integrin-associated ILK and PINCH1 protein content are reduced in skeletal muscle of maintenance hemodialysis patients. J Physiol. Sep 24 2020;doi:10.1113/JP280441

4. Moin ASM, Sathyapalan T, Atkin SL, Butler AE. Pro-fibrotic M2 macrophage markers may increase the risk for COVID19 in type 2 diabetes with obesity. Metabolism. Sep 16 2020;112:154374. doi:10.1016/j.metabol.2020.154374

5. Deshmukh H, Papageorgiou M, Aye M, England J, Abdalla M, Sathyapalan T. Hyperthyroidism and bone mineral density: Dissecting the causal association with Mendelian randomization analysis. Clin Endocrinol (Oxf). Sep 18 2020;doi:10.1111/cen.14330

6. Chattopadhyay S, George A, John J, Sathyapalan T. Post-load glucose spike but not fasting glucose determines prognosis after myocardial infarction in patients without known or newly diagnosed diabetes. J Diabetes. Sep 10 2020;doi:10.1111/1753-0407.13111

7. Butler AE, Ramachandran V, Sathyapalan T, et al. Corrigendum: microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index. Front Endocrinol (Lausanne). 2020;11:515. doi:10.3389/fendo.2020.00515

8. Moin ASM, Sathyapalan T, Atkin SL, Butler AE. Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection? Metabol Open. Sep 2020;7:100052. doi:10.1016/j.metop.2020.100052

9. Butler AE, Hayat S, Dargham SR, et al. Long non-coding RNA expression in non-obese women with polycystic ovary syndrome and weight-matched controls. Reprod Biomed Online. Oct 2020;41(4):579-583. doi:10.1016/j.rbmo.2020.06.018

10. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Obesity and Insulin Resistance: A Review of Molecular Interactions. Curr Mol Med. Aug 12 2020;doi:10.2174/1566524020666200812221527

11. Chattopadhyay S, George A, John J, Sathyapalan T. Two-Hour Post-Load Plasma Glucose, a Biomarker to Improve the GRACE Score in Patients without Known Diabetes. Cardiology. 2020;145(9):553-561. doi:10.1159/000509180

12. Gorabi AM, Kiaie N, Sathyapalan T, Al-Rasadi K, Jamialahmadi T, Sahebkar A. The Role of MicroRNAs in Regulating Cytokines and Growth Factors in Coronary Artery Disease: The Ins and Outs. J Immunol Res. 2020;2020:5193036. doi:10.1155/2020/5193036

13. Abdalla M, Deshmukh H, Atkin SL, Sathyapalan T. miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. Life Sci. Oct 15 2020;259:118174. doi:10.1016/j.lfs.2020.118174

14. Pourtaji A, Jahani V, Sahebkar A, Sathyapalan T, Mohammadpour AH. Application of Erythropoietin in Chronic Heart Failure Treatment. Mini Rev Med Chem. Jul 28 2020;doi:10.2174/1389557520999200728155543

15. Heiat M, Hashemi-Aghdam MR, Heiat F, et al. Integrative role of traditional and modern technologies to combat COVID-19. Expert Rev Anti Infect Ther. Aug 23 2020:1-11. doi:10.1080/14787210.2020.1799784

16. Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820938305. doi:10.1177/2042018820938305

17. Deshmukh H, Wilmot EG, Gregory R, et al. Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care. Sep 2020;43(9):2153-2160. doi:10.2337/dc20-0738

18. Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Renin-Angiotensin System Overactivation in Type 2 Diabetes: A Risk for SARS-CoV-2 Infection? Diabetes Care. Oct 2020;43(10):e131-e133. doi:10.2337/dc20-1115

19. Bahrami A, Sathyapalan T, Moallem SA, Sahebkar A. Counteracting arsenic toxicity: Curcumin to the rescue? J Hazard Mater. Dec 5 2020;400:123160. doi:10.1016/j.jhazmat.2020.123160

20. Kahal H, Halama A, Aburima A, et al. Author Correction: Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. Sci Rep. Jun 19 2020;10(1):10233. doi:10.1038/s41598-020-66189-1

21. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu. Life Sci. Sep 1 2020;256:117916. doi:10.1016/j.lfs.2020.117916

22. Ghazanfarpour M, Sathyapalan T, Banach M, Jamialahmadi T, Sahebkar A. Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. Drug Discov Today. Aug 2020;25(8):1487-1501. doi:10.1016/j.drudis.2020.05.011

23. Kouhpeikar H, Delbari Z, Sathyapalan T, Simental-Mendia LE, Jamialahmadi T, Sahebkar A. The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review. Curr Atheroscler Rep. May 26 2020;22(5):19. doi:10.1007/s11883-020-00837-9

24. Javed Z, Papageorgiou M, Madden LA, et al. The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. Endocr Connect. Jun 2020;9(6):563-569. doi:10.1530/EC-20-0173

25. Omidkhoda N, Vakilian F, Mohammadpour AH, Sathyapalan T, Sahebkar A. Aldosterone and Mineralocorticoid Receptor Antagonists on Pulmonary Hypertension and Right Ventricular Failure: A Review. Curr Pharm Des. 2020;26(31):3862-3870. doi:10.2174/1381612826666200523171137

26. Deshmukh H, Aylward LL, Rose M, et al. Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery. Clin Endocrinol (Oxf). May 21 2020;doi:10.1111/cen.14257

27. Zahedipour F, Hosseini SA, Sathyapalan T, et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytother Res. May 19 2020;doi:10.1002/ptr.6738

28. Butler AE, Ramachandran V, Sathyapalan T, et al. microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index. Front Endocrinol (Lausanne). 2020;11:206. doi:10.3389/fendo.2020.00206

29. Forouzanfar F, Forouzanfar A, Sathyapalan T, Orafai HM, Sahebkar A. Curcumin for the management of periodontal diseases: a review. Curr Pharm Des. May 13 2020;doi:10.2174/1381612826666200513112607

30. Bahrami A, Sathyapalan T, Sahebkar A. The role of interleukin-18 in the development and progression of atherosclerosis. Curr Med Chem. Apr 26 2020;doi:10.2174/0929867327666200427095830

31. Babatabar Darzi H, Vahedian-Azimi A, Ghasemi S, Ebadi A, Sathyapalan T, Sahebkar A. The effect of aromatherapy with rose and lavender on anxiety, surgical site pain, and extubation time after open-heart surgery: A double-center randomized controlled trial. Phytother Res. Apr 8 2020;doi:10.1002/ptr.6698

32. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis. J Diabetes Res. 2020;2020:8768954. doi:10.1155/2020/8768954

33. Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid Med Cell Longev. 2020;2020:8609213. doi:10.1155/2020/8609213

34. Kahal H, Halama A, Aburima A, et al. Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. Sci Rep. Mar 16 2020;10(1):4750. doi:10.1038/s41598-020-61531-z

35. Arasteh O, Nomani H, Baharara H, et al. Antipsychotic Drugs and Risk of Developing Venous Thromboembolism and Pulmonary Embolism: A Systematic Review and Meta-Analysis. Curr Vasc Pharmacol. 2020;18(6):632-643. doi:10.2174/1570161118666200211114656

36. Korani M, Korani S, Zendehdel E, Jaafari MR, Sathyapalan T, Sahebkar A. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib. Anticancer Agents Med Chem. 2020;20(6):643-650. doi:10.2174/1871520620666200127141328

37. Radbakhsh S, Sathyapalan T, Banach M, Sahebkar A. Incretins and microRNAs: Interactions and physiological relevance. Pharmacol Res. Mar 2020;153:104662. doi:10.1016/j.phrs.2020.104662

38. Ashrafizadeh M, Ahmadi Z, Samarghandian S, et al. MicroRNA-mediated regulation of Nrf2 signaling pathway: Implications in disease therapy and protection against oxidative stress. Life Sci. Mar 1 2020;244:117329. doi:10.1016/j.lfs.2020.117329

39. Yaribeygi H, Maleki M, Sathyapalan T, et al. The molecular mechanisms by which vitamin D improve glucose homeostasis: A mechanistic review. Life Sci. Mar 1 2020;244:117305. doi:10.1016/j.lfs.2020.117305

40. Chattopadhyay S, George A, John J, Sathyapalan T. Newly diagnosed abnormal glucose tolerance determines post-MI prognosis in patients with hospital related hyperglycaemia but without known diabetes. J Diabetes Complications. Apr 2020;34(4):107518. doi:10.1016/j.jdiacomp.2019.107518

41. Yaribeygi H, Ashrafizadeh M, Henney NC, Sathyapalan T, Jamialahmadi T, Sahebkar A. Neuromodulatory effects of anti-diabetes medications: A mechanistic review. Pharmacol Res. Feb 2020;152:104611. doi:10.1016/j.phrs.2019.104611

42. Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar A. The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. Biofactors. May 2020;46(3):309-325. doi:10.1002/biof.1597

43. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sci. Jan 15 2020;241:117152. doi:10.1016/j.lfs.2019.117152

44. Jones HS, Papageorgiou M, Gordon A, et al. Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and

application to healthy volunteers: A viable workflow and a cautionary tale. Biochem Pharmacol. Mar 2020;173:113754. doi:10.1016/j.bcp.2019.113754

45. Ganie MA, Sahar T, Rashid A, et al. Comparative Evaluation of Biomarkers of Inflammation Among Indian Women With Polycystic Ovary Syndrome (PCOS) Consuming Vegetarian vs. Non-vegetarian Diet. Front Endocrinol (Lausanne). 2019;10:699. doi:10.3389/fendo.2019.00699

46. Leese HJ, Sathyapalan T, Allgar V, Brison DR, Sturmey R. Going to extremes: the Goldilocks/Lagom principle and data distribution. BMJ Open. Nov 27 2019;9(11):e027767. doi:10.1136/bmjopen-2018-027767

47. Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci. Jan 1 2020;240:117090. doi:10.1016/j.lfs.2019.117090

48. Butler AE, Ramachandran V, Hayat S, et al. Expression of microRNA in follicular fluid in women with and without PCOS. Sci Rep. Nov 8 2019;9(1):16306. doi:10.1038/s41598-019-52856-5

49. Gorabi AM, Hajighasemi S, Sathyapalan T, Sahebkar A. Cell transfer-based immunotherapies in cancer: A review. IUBMB Life. Apr 2020;72(4):790-800. doi:10.1002/iub.2180

50. Yaribeygi H, Maleki M, Sathyapalan T, Sahebkar A. The effect of C-peptide on diabetic nephropathy: A review of molecular mechanisms. Life Sci. Nov 15 2019;237:116950. doi:10.1016/j.lfs.2019.116950

51. Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A. Effects of curcumin on mitochondria in neurodegenerative diseases. Biofactors. Jan 2020;46(1):5-20. doi:10.1002/biof.1566

52. Gorabi AM, Hajighasemi S, Kiaie N, et al. Anti-fibrotic effects of curcumin and some of its analogues in the heart. Heart Fail Rev. Sep 2020;25(5):731-743. doi:10.1007/s10741-019-09854-6

53. La Rosa VL, Ciebiera M, Lin LT, et al. Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. Prz Menopauzalny. Jun 2019;18(2):116-122. doi:10.5114/pm.2019.86836

54. Butler AE, Hayat S, Dargham SR, et al. Alterations in long noncoding RNAs in women with and without polycystic ovarian syndrome. Clin Endocrinol (Oxf). Dec 2019;91(6):793-797. doi:10.1111/cen.14087

55. Al-Qaissi A, Alqarni S, Javed Z, et al. The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine. Nov 2019;66(2):220-225. doi:10.1007/s12020-019-02059-9

56. Korani S, Korani M, Sathyapalan T, Sahebkar A. Therapeutic effects of Crocin in autoimmune diseases: A review. Biofactors. Nov 2019;45(6):835-843. doi:10.1002/biof.1557

57. Kahkhaie KR, Mirhosseini A, Aliabadi A, et al. Correction to: Curcumin: a modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology. Oct 2019;27(5):901. doi:10.1007/s10787-019-00631-3

58. Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. Oct 1 2019;234:116776. doi:10.1016/j.lfs.2019.116776

59. Bibak B, Shakeri F, Barreto GE, Keshavarzi Z, Sathyapalan T, Sahebkar A. A review of the pharmacological and therapeutic effects of auraptene. Biofactors. Nov 2019;45(6):867-879. doi:10.1002/biof.1550

60. Drage DS, Heffernan AL, Cunningham TK, et al. Serum measures of hexabromocyclododecane (HBCDD) and polybrominated diphenyl ethers (PBDEs) in reproductive-aged women in the United Kingdom. Environ Res. Oct 2019;177:108631. doi:10.1016/j.envres.2019.108631

61. Jervis W, Shah N, Mongolu SK, Sathyapalan T. Severe proximal myopathy secondary to Hashimoto's thyroiditis. BMJ Case Rep. Jul 27 2019;12(7)doi:10.1136/bcr-2019-230427

62. Reyes-Munoz E, Guardo FD, Ciebiera M, et al. Diet and Nutritional Interventions with the Special Role of Myo-Inositol in Gestational Diabetes Mellitus Management. An Evidence-Based Critical Appraisal. Curr Pharm Des. 2019;25(22):2467-2473. doi:10.2174/1381612825666190722155512

63. Sathyapalan T, Hobkirk JP, Javed Z, et al. The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2019;10:394. doi:10.3389/fendo.2019.00394

64. Papageorgiou M, Kerschan-Schindl K, Sathyapalan T, Pietschmann P. Is Weight Loss Harmful for Skeletal Health in Obese Older Adults? Gerontology. 2020;66(1):2-14. doi:10.1159/000500779

65. Yaribeygi H, Yaribeygi A, Sathyapalan T, Sahebkar A. Molecular mechanisms of trehalose in modulating glucose homeostasis in diabetes. Diabetes Metab Syndr. May - Jun 2019;13(3):2214-2218. doi:10.1016/j.dsx.2019.05.023

66. Keshavarzi Z, Shakeri F, Barreto GE, Bibak B, Sathyapalan T, Sahebkar A. Medicinal plants in traumatic brain injury: Neuroprotective mechanisms revisited. Biofactors. Jul 2019;45(4):517-535. doi:10.1002/biof.1516

67. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. Jul 2019;7(7):515-527. doi:10.1016/S2213-8587(19)30192-5

68. Yaribeygi H, Lhaf F, Sathyapalan T, Sahebkar A. Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage. Life Sci. Aug 15 2019;231:116538. doi:10.1016/j.lfs.2019.06.013

69. Alkandari A, Ashrafian H, Sathyapalan T, et al. Bariatric Surgery Modulates Urinary Levels of MicroRNAs Involved in the Regulation of Renal Function. Front Endocrinol (Lausanne). 2019;10:319. doi:10.3389/fendo.2019.00319

70. Konya J, Sathyapalan T, Kilpatrick ES, Atkin SL. The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. Front Endocrinol (Lausanne). 2019;10:296. doi:10.3389/fendo.2019.00296

71. Kahkhaie KR, Mirhosseini A, Aliabadi A, et al. Curcumin: a modulator of inflammatory signaling pathways in the immune system. Inflammopharmacology. Oct 2019;27(5):885-900. doi:10.1007/s10787-019-00607-3

72. Ramanjaneya M, Jerobin J, Bettahi I, et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin Endocrinol (Oxf). Aug 2019;91(2):278-287. doi:10.1111/cen.14007

73. Rahimi K, Ahmadi A, Hassanzadeh K, et al. Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states. Autoimmun Rev. Jul 2019;18(7):738-748. doi:10.1016/j.autrev.2019.05.012

74. Chattopadhyay S, George A, John J, Sathyapalan T. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. Diab Vasc Dis Res. Nov 2019;16(6):489-497. doi:10.1177/1479164119845561

75. Swart AC, Johannes ID, Sathyapalan T, Atkin SL. The Effect of Soy Isoflavones on Steroid Metabolism. Front Endocrinol (Lausanne). 2019;10:229. doi:10.3389/fendo.2019.00229

76. Tabeshpour J, Banaeeyeh S, Eisvand F, Sathyapalan T, Hashemzaei M, Sahebkar A. Effects of curcumin on ion channels and pumps: A review. IUBMB Life. Jul 2019;71(7):812-820. doi:10.1002/iub.2054

77. Dawson AJ, Sathyapalan T, Vince R, et al. The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2019;10:189. doi:10.3389/fendo.2019.00189

78. Rezaei H, Khadempar S, Farahani N, et al. Harnessing CRISPR/Cas9 technology in cardiovascular disease. Trends Cardiovasc Med. Feb 2020;30(2):93-101. doi:10.1016/j.tcm.2019.03.005

79. Paseban M, Mohebbati R, Niazmand S, Sathyapalan T, Sahebkar A. Comparison of the Neuroprotective Effects of Aspirin, Atorvastatin, Captopril and Metformin in Diabetes Mellitus. Biomolecules. Mar 27 2019;9(4)doi:10.3390/biom9040118

80. Javed Z, Papageorgiou M, Deshmukh H, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf). Jun 2019;90(6):805-813. doi:10.1111/cen.13968

81. Otun J, Sahebkar A, Ostlundh L, Atkin SL, Sathyapalan T. Systematic Review and Meta-analysis on the Effect of Soy on Thyroid Function. Sci Rep. Mar 8 2019;9(1):3964. doi:10.1038/s41598-019-40647-x

82. Alalami H, Sathyapalan T, Atkin SL. Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2019;10:2042018818805674. doi:10.1177/2042018818805674

83. Cunningham TK, Allgar V, Dargham SR, et al. Association of Vitamin D Metabolites With Embryo Development and Fertilization in Women With and Without PCOS Undergoing Subfertility Treatment. Front Endocrinol (Lausanne). 2019;10:13. doi:10.3389/fendo.2019.00013

84. Javed Z, Papageorgiou M, Deshmukh H, et al. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. Nutrients. Jan 17 2019;11(1)doi:10.3390/nu11010188

85. Halama A, Kahal H, Bhagwat AM, et al. Metabolic and proteomic signatures of hypoglycaemia in type 2 diabetes. Diabetes Obes Metab. Apr 2019;21(4):909-919. doi:10.1111/dom.13602

86. Sathyapalan T, Kohrle J, Rijntjes E, et al. The Effect of High Dose Isoflavone Supplementation on Serum Reverse T3 in Euthyroid Men With Type 2 Diabetes and Post-menopausal Women. Front Endocrinol (Lausanne). 2018;9:698. doi:10.3389/fendo.2018.00698

87. Papageorgiou M, Sathyapalan T, Schutte R. Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women. J Cachexia Sarcopenia Muscle. Feb 2019;10(1):131-139. doi:10.1002/jcsm.12359

88. Deshmukh H, Papageorgiou M, Kilpatrick ES, Atkin SL, Sathyapalan T. Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. Clin Endocrinol (Oxf). Jan 2019;90(1):162-169. doi:10.1111/cen.13879

89. Al-Qaissi A, Papageorgiou M, Javed Z, et al. Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus. Diabetes Obes Metab. Mar 2019;21(3):569-574. doi:10.1111/dom.13555

90. Reyes-Munoz E, Sathyapalan T, Rossetti P, et al. Polycystic Ovary Syndrome: Implication for Drug Metabolism on Assisted Reproductive Techniques-A Literature Review. Adv Ther. Nov 2018;35(11):1805-1815. doi:10.1007/s12325-018-0810-1

91. Al-Qaissi A, Papageorgiou M, Deshmukh H, et al. Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes. Diabetes Obes Metab. Mar 2019;21(3):533-540. doi:10.1111/dom.13548

92. Sathyapalan T, Dawson AJ, Rigby AS, Thatcher NJ, Kilpatrick ES, Atkin SL. The Effect of Phytoestrogen on Thyroid in Subclinical Hypothyroidism: Randomized, Double Blind, Crossover Study. Front Endocrinol (Lausanne). 2018;9:531. doi:10.3389/fendo.2018.00531

93. Papageorgiou M, Wells L, Williams C, et al. Occurrence of deoxynivalenol in an elderly cohort in the UK: a biomonitoring approach. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. Oct 2018;35(10):2032-2044. doi:10.1080/19440049.2018.1508890

94. Heffernan AL, Cunningham TK, Drage DS, et al. Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. Int J Hyg Environ Health. Aug 2018;221(7):1068-1075. doi:10.1016/j.ijheh.2018.07.009

95. Konya J, Spurgeon BEJ, Al Qaissi A, et al. Corrigendum: The Effect of a Simulated Commercial Flight Environment With Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants With Type 2 Diabetes - A Cross-Over Study. Front Endocrinol (Lausanne). 2018;9:301. doi:10.3389/fendo.2018.00301

96. Alkandari A, Ashrafian H, Sathyapalan T, et al. Improved physiology and metabolic flux after Roux-en-Y gastric bypass is associated with temporal changes in the circulating microRNAome: a longitudinal study in humans. BMC Obes. 2018;5:20. doi:10.1186/s40608-018-0199-z

97. Kahal H, Aburima A, Spurgeon B, et al. Platelet function following induced hypoglycaemia in type 2 diabetes. Diabetes Metab. Nov 2018;44(5):431-436. doi:10.1016/j.diabet.2018.04.004

98. Sathyapalan T, Aye M, Rigby AS, et al. Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. Nutr Metab Cardiovasc Dis. Jul 2018;28(7):691-697. doi:10.1016/j.numecd.2018.03.007

99. Chattopadhyay S, George A, John J, Sathyapalan T. Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes. Eur Heart J. Aug 1 2018;39(29):2740-2745. doi:10.1093/eurheartj/ehy233

100. Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency. Front Endocrinol (Lausanne). 2018;9:56. doi:10.3389/fendo.2018.00056

101. Chattopadhyay S, George A, John J, Sathyapalan T. Correction to: Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes. Acta Diabetol. May 2018;55(5):459. doi:10.1007/s00592-018-1122-2

102. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Keevil B, Atkin SL. Salivary and serum androgens with anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Sci Rep. Feb 28 2018;8(1):3795. doi:10.1038/s41598-018-22176-1

103. Konya J, Spurgeon BEJ, Al Qaissi A, et al. The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes - A Cross-over Study. Front Endocrinol (Lausanne). 2018;9:26. doi:10.3389/fendo.2018.00026

104. Chattopadhyay S, George A, John J, Sathyapalan T. Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes. Acta Diabetol. May 2018;55(5):449-458. doi:10.1007/s00592-018-1114-2

105. Papageorgiou M, Wells L, Williams C, et al. Assessment of Urinary Deoxynivalenol Biomarkers in UK Children and Adolescents. Toxins (Basel). Jan 23 2018;10(2)doi:10.3390/toxins10020050

106. Sathyapalan T, Javed Z, Rigby AS, Kilpatrick ES, Atkin SL. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. J Endocr Soc. May 1 2017;1(5):423-430. doi:10.1210/js.2016-1068

107. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Atkin SL. Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). Feb 2018;88(2):258-262. doi:10.1111/cen.13517

108. Sathyapalan T, Aye M, Rigby AS, Fraser WD, Kilpatrick ES, Atkin SL. Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - a randomised controlled study. Sci Rep. Nov 13 2017;7(1):15366. doi:10.1038/s41598-017-15402-9

109. O'Doherty AF, Jones HS, Sathyapalan T, Ingle L, Carroll S. The Effects of Acute Interval Exercise and Strawberry Intake on Postprandial Lipemia. Med Sci Sports Exerc. Nov 2017;49(11):2315-2323. doi:10.1249/MSS.0000000000001341

110. Sathyapalan T, Coady AM, Kilpatrick ES, Atkin SL. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocr Connect. Nov 2017;6(8):811-816. doi:10.1530/EC-17-0217

111. Gonzalez S, Windram JD, Sathyapalan T, Javed Z, Clark AL, Atkin SL. Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. J Int Med Res. Dec 2017;45(6):1708-1719. doi:10.1177/0300060517723798

112. Sathyapalan T, Dickerson EH, Maguiness SM, Robinson J, Dakroury YHZ, Atkin SL. Androstenedione and testosterone levels correlate with in vitro fertilization rates in insulin-resistant women. BMJ Open Diabetes Res Care. 2017;5(1):e000387. doi:10.1136/bmjdrc-2017-000387

113. Dawson AJ, Kilpatrick ES, Coady AM, et al. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord. Jul 14 2017;17(1):41. doi:10.1186/s12902-017-0194-2

114. Wells L, Hardie L, Williams C, et al. Deoxynivalenol Biomarkers in the Urine of UK Vegetarians. Toxins (Basel). Jun 22 2017;9(7)doi:10.3390/toxins9070196

115. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, et al. Salivary testosterone measurement in women with and without polycystic ovary syndrome. Sci Rep. Jun 15 2017;7(1):3589. doi:10.1038/s41598-017-03945-w

116. Cho LW, Sathyapalan T, Kilpatrick ES, et al. Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. BMC Endocr Disord. May 19 2017;17(1):26. doi:10.1186/s12902-017-0177-3

117. Sathyapalan T, Rigby AS, Bhasin S, Thatcher NJ, Kilpatrick ES, Atkin SL. Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism: A Randomized Controlled Study. J Clin Endocrinol Metab. Feb 1 2017;102(2):425-433. doi:10.1210/jc.2016-2875

118. Wells L, Hardie L, Williams C, et al. Determination of Deoxynivalenol in the Urine of Pregnant Women in the UK. Toxins (Basel). Oct 25 2016;8(11)doi:10.3390/toxins8110306

119. O'Doherty AF, Sathyapalan T, Rigby AS, Ingle L, Carroll S. The repeatability of the abbreviated (4-h) Oral Fat Tolerance Test and influence of prior acute aerobic exercise. Eur J Nutr. Feb 2018;57(1):309-318. doi:10.1007/s00394-016-1320-z

120. Simintiras CA, Frohlich T, Sathyapalan T, et al. Modelling oviduct fluid formation in vitro. Reproduction. Oct 13 2016;doi:10.1530/REP-15-0508

121. Sathyapalan T, Javed Z, Kilpatrick ES, Coady AM, Atkin SL. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). Mar 2017;86(3):384-387. doi:10.1111/cen.13239

122. Greetham S, Goodwin S, Wells L, et al. Pilot Investigation of a Virtual Gastric Band Hypnotherapy Intervention. Int J Clin Exp Hypn. Oct-Dec 2016;64(4):419-33. doi:10.1080/00207144.2016.1209037

123. Sathyapalan T, Aye M, Rigby AS, et al. Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial. J Bone Miner Res. Jan 2017;32(1):157-164. doi:10.1002/jbmr.2927

124. Sathyapalan T, Dakroury Y, Ahmed L, et al. Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). Oct 2016;85(4):671-3. doi:10.1111/cen.13120

125. Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther Adv Endocrinol Metab. Feb 2016;7(1):12-23. doi:10.1177/2042018815616543

126. Javed Z, Qamar U, Sathyapalan T. Pituitary and/or hypothalamic dysfunction following moderate to severe traumatic brain injury: Current perspectives. Indian J Endocrinol Metab. Nov-Dec 2015;19(6):753-63. doi:10.4103/2230-8210.167561

127. Javed Z, Qamar U, Sathyapalan T. The role of kisspeptin signalling in the hypothalamic-pituitary-gonadal axis--current perspective. Endokrynol Pol. 2015;66(6):534-47. doi:10.5603/EP.2015.0066

128. Sathyapalan T, David R, Gooderham NJ, Atkin SL. Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Sci Rep. Nov 19 2015;5:16890. doi:10.1038/srep16890

129. George A, Bhatia RT, Buchanan GL, et al. Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study. PLoS One. 2015;10(11):e0142045. doi:10.1371/journal.pone.0142045

130. Sathyapalan T, Thatcher NJ, Hammersley R, et al. Aspartame sensitivity? A double blind randomised crossover study. PLoS One. 2015;10(3):e0116212. doi:10.1371/journal.pone.0116212

131. Mellor DD, Sathyapalan T, Kilpatrick ES, Atkin SL. Diabetes and chocolate: friend or foe? J Agric Food Chem. Nov 18 2015;63(45):9910-8. doi:10.1021/acs.jafc.5b00776

132. Sathyapalan T, Atkin SL, Kilpatrick ES. LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation. Ann Clin Biochem. Jan 2015;52(Pt 1):180-2. doi:10.1177/0004563214533515

133. Dawson AJ, Sathyapalan T, Sedman P, Ajjan R, Kilpatrick ES, Atkin SL. Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls. Obes Surg. Mar 2014;24(3):349-58. doi:10.1007/s11695-013-1100-2

134. Kamalanathan S, Sahoo JP, Sathyapalan T. Pregnancy in polycystic ovary syndrome. Indian J Endocrinol Metab. Jan 2013;17(1):37-43. doi:10.4103/2230-8210.107830

135. Dawson AJ, Sathyapalan T, Smithson JA, et al. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). Jun 2014;80(6):843-9. doi:10.1111/cen.12258

136. Dawson AJ, Sathyapalan T, Atkin SL, Kilpatrick ES. Biological variation of cardiovascular risk factors in patients with diabetes. Diabet Med. Oct 2013;30(10):1172-80. doi:10.1111/dme.12160

137. Sathyapalan T, Shepherd J, Atkin SL, Kilpatrick ES. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab. Aug 2013;15(8):767-9. doi:10.1111/dom.12074

138. Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. Nov 2012;97(11):3951-5. doi:10.1210/jc.2012-2279

139. Sathyapalan T, Dixit S. Radiotherapy-induced hypopituitarism: a review. Expert Rev Anticancer Ther. May 2012;12(5):669-83. doi:10.1586/era.12.27

140. Shor D, Sathyapalan T, Atkin SL, Thatcher NJ. Does equol production determine soy endocrine effects? Eur J Nutr. Jun 2012;51(4):389-98. doi:10.1007/s00394-012-0331-7

141. Sathyapalan T, Atkin SL. Recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol. Apr 2012;166(4):575-83. doi:10.1530/EJE-11-0755

142. Dickerson EH, Sathyapalan T, Knight R, et al. Endocrine disruptor & nutritional effects of heavy metals in ovarian hyperstimulation. J Assist Reprod Genet. Dec 2011;28(12):1223-8. doi:10.1007/s10815-011-9652-3

143. Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem. Jan 2012;49(Pt 1):80-5. doi:10.1258/acb.2011.011071

144. Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf). Feb 2012;76(2):196-200. doi:10.1111/j.1365-2265.2011.04197.x

145. Sathyapalan T, Aye MM, Atkin SL. Postural hypotension. BMJ. Jun 16 2011;342:d3128. doi:10.1136/bmj.d3128

146. Thong KY, Jose B, Blann AD, et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract. Aug 2011;93(2):e87-e91. doi:10.1016/j.diabres.2011.05.015

147. Wakil A, Sathyapalan T, Atkin SL. Pituitary hypophysitis and gulf war syndrome: a case series and hypothesis. Clin Endocrinol (Oxf). Aug 2011;75(2):272-4. doi:10.1111/j.1365-2265.2011.04025.x

148. Sathyapalan T, Atkin SL. Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes? Minerva Endocrinol. Jun 2011;36(2):147-56.

149. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab. Aug 2011;13(8):703-10. doi:10.1111/j.1463-1326.2011.01393.x

150. Sathyapalan T, Manuchehri AM, Thatcher NJ, et al. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. May 2011;96(5):1442-9. doi:10.1210/jc.2010-2255

151. Kahal H, Atkin SL, Sathyapalan T. Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J Obes. 2011;2011:402052. doi:10.1155/2011/402052

152. Dawson AJ, Mellor DD, Sathyapalan T, Kilpatrick ES, Atkin SL. Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant. Diabet Med. Jan 2011;28(1):124-5. doi:10.1111/j.1464-5491.2010.03145.x

153. Sathyapalan T, Beckett S, Rigby AS, Mellor DD, Atkin SL. High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome. Nutr J. Nov 22 2010;9:55. doi:10.1186/1475-2891-9-55

154. Mellor DD, Sathyapalan T, Kilpatrick ES, Beckett S, Atkin SL. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. Diabet Med. Nov 2010;27(11):1318-21. doi:10.1111/j.1464-5491.2010.03108.x

155. Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem. Nov 2010;56(11):1696-700. doi:10.1373/clinchem.2010.144014

156. Sathyapalan T, Atkin SL, Kilpatrick ES. Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes Care. Sep 2010;33(9):1948-50. doi:10.2337/dc10-0201

157. Sathyapalan T, Atkin SL, Kilpatrick ES. Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement? Diabetes Obes Metab. Jun 2010;12(6):540-4. doi:10.1111/j.1463-1326.2009.01190.x

158. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm. 2010;2010:758656. doi:10.1155/2010/758656

159. Sathyapalan T, Manuchehri AM, Rigby AS, Atkin SL. Subclinical hypothyroidism is associated with reduced all-cause mortality in patients with type 2 diabetes. Diabetes Care. Mar 2010;33(3):e37. doi:10.2337/dc09-1555

160. Sathyapalan T, Atkin SL. Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab. Feb 2010;1(1):15-22. doi:10.1177/2042018810367984

161. Sathyapalan T, Mellor D, Atkin SL. Obesity and gestational diabetes. Semin Fetal Neonatal Med. Apr 2010;15(2):89-93. doi:10.1016/j.siny.2009.09.002

162. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). Apr 2010;72(4):566-8. doi:10.1111/j.1365-2265.2009.03678.x

163. Sathyapalan T, Gonzalez S, Atkin SL. Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric. Oct 2009;12(5):427-30. doi:10.1080/13697130902929559

164. Sathyapalan T, Cho L, Kilpatrick ES, Le Roux CW, Coady AM, Atkin SL. Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). Mar 2010;72(3):423-5. doi:10.1111/j.1365-2265.2009.03643.x

165. Sathyapalan T, Atkin SL. Investigating hirsutism. BMJ. Apr 28 2009;338:b912. doi:10.1136/bmj.b912

166. Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). Jan 2009;70(1):124-8. doi:10.1111/j.1365-2265.2008.03345.x

167. Sathyapalan T, Atkin SL, Kilpatrick ES. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabet Med. Aug 2008;25(8):909-15. doi:10.1111/j.1464-5491.2008.02519.x

168. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. Jan 2009;94(1):103-8. doi:10.1210/jc.2008-1750

169. Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin Endocrinol (Oxf). Dec 2008;69(6):931-5. doi:10.1111/j.1365-2265.2008.03260.x

170. Manuchehri AM, Sathyapalan T, Jayagopal V, et al. Alterations in thyroid status do not affect plasma peptide YY (PYY) and ghrelin concentrations. Clin Endocrinol (Oxf). May 2008;68(5):836-8. doi:10.1111/j.1365-2265.2007.03093.x

171. Manuchehri AM, Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Pituitary. 2007;10(3):261-6. doi:10.1007/s11102-007-0048-4

172. Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary. 2007;10(3):233-6. doi:10.1007/s11102-007-0044-8

173. Mistry D, Maung KH, Manuchehri AM, Sathyapalan T, Atkin S, England J. Key developments in endocrinology. Practitioner. Aug 2005;249(1673):541, 543-7, 549 passim.

 

Non indexed publications

  1. Crabtree TSJ, Wilmot E, Sathyapalan T 2018. Freestyle Libre: available on the NHS? The British Journal of Diabetes: 18:1
  2. Abiola D, Sathyapalan T, Hepburn D 2016 Management of type 1 and type 2 diabetes requiring insulin. Prescriber 27.09
  3. Mackenzie G, Boa AN, Taboada AD, Atkin SL, Sathyapalan T. 2015 Sporopollenin, the least known yet toughest natural biopolymer Mini Review, Front. Mater. - Polymer Chemistry. DOI: 10.3389/fmats.2015.00066
  4. Kadiyala P, Walton S, Sathyapalan T. 2015. Insulin induced lipodystrophy. Br J Diabetes Vasc Dis 2014;14:131-133.
  5. Sathyapalan T. 2015 The environmental obesogen hypothesis for diabesity.
Postgraduate research supervision
Current students

Najeeb Shah (MD) - Interventions on metabolic fluctuations on type 2 diabetes
Principal Supervisor: Professor Thozhukat Sathyapalan

Haidee Gonzalez (MD) - To evaluate the link between obesity, metabolic syndrome, hyperlipidaemia, NAFLD in inflammatory bowel disease
Principal Supervisor: Professor Thozhukat Sathyapalan

Mohammed Abdalla (PhD) - Pharmacotherapy of PCOS
Principal Supervisor: Professor Thozhukat Sathyapalan

Katie Bird (MD) - Evaluation of pharmacology prescribing assessment for undergraduate medical students
Principal Supervisor: Professor Thozhukat Sathyapalan

Alexandra Macnamara (MD) - Evaluation of pharmacology teaching for undergraudate medical students
Principal Supervisor: Professor Thozhukat Sathyapalan

Mo Aye (PhD) - Hull Hip fracture Intervention and Prevention Programme (HHIPP) (PhD 2019-2022) OSPREY (Osteoporosis research charity)
Principal Supervisor: Professor Thozhukat Sathyapalan

Youssra HZ Dakroury (MSc) - Vitamin D effects in Qatari population (MSc 2019-2020), Weill Cornell at Qatar
Principal Supervisor: Professor Thozhukat Sathyapalan

Saeed Alqarni (PhD) - Endoparticle profile in patients with type 2 diabetes
Co-supervisor: Professor Thozhukat Sathyapalan

Completed students

Alexandra Butler (PhD) - Life, Death and Regeneration for the Beta Cell (2020)
Principal Supervisor: Professor Thozhukat Sathyapalan

James England (MD) - Parameters for parathyroid surgery in hyperparathyroidism (2019)
Principal Supervisor: Professor Thozhukat Sathyapalan

Zeeshan Javed (PhD) - The effect of vitamin D in women with PCOS (2018)
Diabetes and Endocrinology research fund
Principal Supervisor: Professor Thozhukat Sathyapalan

Ahmed Al-Qaissi (MD) - The studies on the physiology of insulin action in patients with diabetes mellitus. (2018)
Principal Supervisor: Professor Thozhukat Sathyapalan

Alasdair O Doherty (PhD) - Effect of exercise of post-prandial hyperlipidaemia. (2016)
Co-supervisor: Professor Thozhukat Sathyapalan

Keith Cunningham (MD) -The impact of insulin resistance and polycystic ovary syndrome on IVF outcomes. (2016)
Principal Supervisor: Professor Thozhukat Sathyapalan

Ehtesham Ehtesham (PhD) - Effects of dietary polyphenols on vascular endothelium and cardiovascular health. (2016)
Principal Supervisor: Professor Thozhukat Sathyapalan

Constantine Simintiras (PhD) - The in vitro modelling of the oviduct: Investigating the role of maternal metabolic and endocrine parameters on early embryonic stem cell development (2014)
Co-supervisor: Professor Thozhukat Sathyapalan

Anish George (MD) - Effect of dysglycaemia on cardiovascular outcome following acute coronary syndrome. (2015)
Principal Supervisor: Professor Thozhukat Sathyapalan

Hassan Kahal (PhD) - The effect of liraglutide on platelet function and atherothormbotic risk in women with polycystic ovary syndrome (2015)
Principal Supervisor: Professor Thozhukat Sathyapalan

Judit Konya (MD) - Effect of polyphenols in cardiovascular risk factors. (2015)
Principal Supervisor: Professor Thozhukat Sathyapalan

Simon Adams (MD) - Identification of factors predictive of outcome following bariatric surgery (2013)
Principal Supervisor: Professor Thozhukat Sathyapalan

External roles

Administrative roles

· Chair of Hull York Medical School Ethics committee (2016 – to date)

· Lead the Academic Endocrinology, Diabetes and Metabolism Group at HYMS

· Lead the Endocrinology Comprehensive Research Network for Yorkshire and Humber

· Deputy lead for the Diabetes Comprehensive Research Network for Yorkshire and Humber.

· Member of NIHR CRN national committee for metabolic and endocrine disorders.

 

National Committees

· Association of British Clinical Diabetologists (ABCD) National Committee: 2013 – to date

· National UK lead for Freestyle Libre audit: 2018 – to date

· British Society for Endocrinology, National Clinical Committee: 2014 – 2018; 2020 – to date

· UKI NETS Clinical Practice Committee: 2015 – to date

· Member of European Neuroendocrine Tumour Society 2017 – to date

· Steering Committee for the UK Acromegaly Register: 2016 – 2020

· National Institute of Health Research, Health Technology Assessment, Diagnostic Technologies & Screening Programmes (DTSP) Panel member: 2013-15

· Member of Steering Group – ABCD Nationwide Exenatide/Liraglutide Audit: 2013-18

· Member of Strategic Clinical Network Board (Diabetes), Yorkshire and Humber Group

· Member and key stakeholder in the Acne Priority Setting Partnership, James Lind Alliance.

· Chairman of Pit Pat, Hull (local branch of Pituitary Foundation, patient support group, UK)

 

Membership of professional bodies

· American College of Physicians

· British Endocrine Society

· American Endocrine Society

· Royal College of Physicians (Edinburgh)

· Royal College of Physicians (London

· Association of British Clinical Diabetologists

· European neuroendocrine tumour society

· Senior Fellow of Higher Education Academy

Editorial board

· Scientific Reports (Nature Publishing Group)

· Clinical Endocrinology

· British Journal of Diabetes (Associate Editor)

· Frontiers in Diabetes (Associate Editor)

· Therapeutic Advances in Endocrinology and Metabolism

External examiner roles

· PhD/MD external examiner for University of Warwick; Imperial College, London; University of Cardiff; JIPMER, India

· Royal Colleges of Physicians PACES examiner: (2012 – to date)

· External examiner for Diploma and MSc courses in Diabetes and Endocrinology, University of South Wales, UK (2013-16)

· External examiner for Diabetes MSc, PGDip, PGCert – University of Leicester – distant learning module (2017 – to date )

· External examiner for Diabetes MSc, PGDip, PGCert – University of Leicester – campus module (2019 – to date)